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Abstract 
Proteome analysis is a complex and dynamic process that encompasses several analytical platforms 
that include protein sequencing, structural or expression proteomics, protein modification, sub-cellular 
protein localization, protein-protein interaction and biological functional proteomics. In fact, expression 
proteomics is extensively applied in a majority of biomarker detection studies because it provides a 
detailed overview of differentially expressed proteins in cellular pathways and disease processes. 
Proteomics are also effective and dynamic in protein-protein interactions and cross-talks between 
interacting molecules of the cell. Proteomics has evolved into a crucial tool used to investigate the 
biochemical changes that possibly lead to development of cancer biomarkers. This review draws 
attention to the progress and advancements in cancer proteomics technology with the aim of simplifying 
the understanding of the mechanisms underlying the disease and to contribute to detection of 
biomarkers in addition to the development of novel treatments. Given that proteome is a dynamic entity 
of cellular functions in health and disease, it is capable of reflecting the immediate environmental state 
of cells and tissues as shown in this review. The review shows the possibility of elucidating the 
pathophysiology of acute myeloid leukaemia (AML) through proteome expressions, thus confirming the 
viability of proteome analysis in profiling AML. 
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Acute myeloid leukemia (AML) is an invasive 
hematological cancer that affects different clonal 
hematopoietic cells leading to distinct differences 
in their response to chemotherapy treatment [1]. 
Despite advancement in leukemia therapy, the 
mortality rate remains high as a result of disease 
progression. In 2012, United States recorded 
deaths of 10,200 out of 13,780 AML cases 
(mortality rate of 74 %) with majority of the 
patients unable to withstand chemotherapy [2]. 
This is due to the fact that hematopoietic stem 
cells (HSCs) in AML persist in an immature state 
because their development or differentiation is 
impeded at the level of progenitor cells resulting 
in malignant production and accumulation of 
leukemic cells [3]. 
 
Malignant cancer cells frequently exhibit 
abnormal expression of metabolic and signaling 
pathways of proteins [4]. Therefore, the 
classification of AML depends on morphological, 
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cytochemical and immunophenotypic cellular 
characteristics. These cellular characteristics are 
defined by the molecular entities, which could be 
targeted for the development of diagnostic and 
prognostic profiles, and for the identification of 
disease subtypes [5]. The genome and their 
respective proteins have recently become 
valuable tools in hematology research. It is 
established that genetic changes result in altered 
cellular processes, which in turn affect 
differentiation, growth control and induce 
apoptosis. Proteins are workforce and thrust for 
nearly every cellular metabolic processes and 
serve in the functional mechanism for cells, 
tissues or organs [6]. 
 
Recent advancements in proteomic technologies 
have garnered immense interest in the search for 
biomarkers for different hematological 
malignancies. Comprehensive analysis of 
proteins from cells, tissues, fluids, or organs, 
using the classical proteomic platforms has 
provided data on the disease heterogeneity at 
different phases of growth and progression. 
Therefore, proteomics are currently increasingly 
being sought in cancer research to characterize 
abnormally expressed proteins that could 
potentially be used as disease biomarkers [6]. 
These biomarkers would complement the more 
conventional diagnostic techniques such as 
cytogenetics, hematology, and other clinical tests 
to effectively diagnose and offer prognosis of 
AML, in addition to minimizing the use of invasive 
procedures like bone marrow and tissue biopsies 
[7,8]. 
 
Synopsis of proteomics techniques  
 
Proteomes are the outcomes of the expression of 
thousands of genes. The complexities associated 
with proteome identification can be attributed to 
the presence of posttranslational modifications 
(PTMs) and large variation in dynamic ranges. 
Therefore, simplifying the mechanism of 
proteomes would increase the efficiency of the 
analysis. Accordingly, a considerable part of 
proteomic research is devoted to the 
improvement of separation techniques in order to 
better resolve complex proteomes [9, 10]. 
Regardless of the advancement in liquid 
chromatography, there remains the need to study 
proteomics comprehensively (top-down and 
bottom-up proteomics) to improve the 
understanding of cell biology [11]. This is 
inevitable because it is very difficult to depend on 
one method or equipment to identify and quantify 
components of a complex protein sample in a 
simple, single-step operation. Several tools and 
procedures are required in separation and 
identification of polypeptides in addition to 
integrating and analysis of data.  
 
The major separation tools used in proteomic 
identification comprise gel-based proteomics, 
ionization methods, mass spectrometry tools, 
and quantification approaches [12]. The two-
dimension electrophoresis (2-DE) is based on 
separation of proteins on two independent 
parameters of charge and molecular mass in an 
electric field and it is the most efficient and high-
resolution protein separation method for complex 
mixture of samples. These methods are 
presently well-optimized and are regularly 
applied in proteomics analysis [13,5]. Proteomic 
mass spectroscopy-based platforms are used to 
identify large numbers of novel proteins with the 
potential to be biomarkers. The strategies of 
proteomic biomarkers involve the identification of 
markers using multidimensional protein 
identification technology coupled with mass 
spectroscopic identification [14]. Fluorescence in 
situ hybridization (FISH) is used to monitor 
diseases and identify specific abnormalities. The 
FISH probes the following abnormalities: t 
(15;17) translocation, t (8;21) translocation, 
inversion (16), 11q23,+8, +21, +22 del(7q), which 
are used to identify prognostically important 
translocations in newly diagnosed AML [15].The 
current usage of computational systems to 
analyze data related to biomolecules on a large-
scale platform has become a crucial and firmly 
recognized discipline in molecular biology. 
Bioinformatics science has become vital to 
biological research because of its use in 
managing large volume of records and 




The strategy adopted in this study is to search for 
the related articles archived in the Science Direct 
database using selected key words, specifically, 
‘acute myeloid leukaemia’ and ‘proteomics’. The 
database was searched for papers published 
between February, 2012 and February, 2016. 
This review only cited the available research 
articles related to AML and it does not include 
books, conference proceedings and reviews. The 
studies were represented in a descending order 
from 2016 to 2012. 
 
Generally, most of the studies exploring AML 
were done using AML patient samples or cell 
lines and few studies used aptamer and 
retrospective analysis. As depicted in Figure 1, 8 
articles comprising around 44.4 % of total 
publications investigated AML using human 
samples, while 7 articles (38.9 %) used cell lines. 
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Figure 1: Numbers and percentages of publications 
related to acute myeloid leukaemia from February 
2012 till February 2016 classified according to type of 
sample used. HAPD; high abundance protein 
depletion, RA; retrospective analysis 
 
Review of studies highlighting proteomic 
profiles of acute myeloid leukaemia 
 
Studies exploring the proteomic profiles of AML 
from 2016 to 2012 are summarized in Table 1a 
and 1b according to the Science Direct website. 
It summarizes the aims of previous studies, 
methods used in investigation, sample number, 
and sample type. 
 
In a recent study, the association between 
BCL11A expression at diagnosis and clinical 
outcomes in newly-diagnosed persons suffering 
from AML was assessed. They explicitly used 
reverse transcriptase and real-time polymerase 
chain reaction (RT-PCR) to determine levels of 
BCL11A mRNA in bone marrow and blood 
mononuclear cells in 292 consecutive newly-
diagnosed subjects affected with AML. The data 
was afterward comparatively analyzed against 
mRNA levels in bone marrow cells of normal 
individuals. TheBCL11A transcript levels of 
subjects at the time of diagnosis exceeded the 
median value of 2.434 (± 3.423 SD; 25th – 75th 
inter-quartile range, 1.33 – 4.29). White blood 
cell (WBC) levels was found to be high and the 
main fraction of bone marrow myoblasts were 
classified as FAB M0 subtype and less possibility 
of being FAB M3 subtype, and is thus more 
prone to be in the intermediate cytogenetic risk 
cohort and less likely to have a complex 
karyotype and more likely to have DNMT3AR882 
and FLT3-ITD mutations than subjects with 
transcript levels below the median value. 89 
persons were subjected to conventional induction 
chemotherapy. The complete remission rate in 
the 89 subjects was reported to be 54 % with 95 
% confidence interval (CI); 33, 75 %) in the lower 
BCL11A cohort and 65 % (45, 85  %,(p = 0.26) in 
the higher BCL11A group. 3 year survival was 33 
% (2, 65 %) in the lower BCL11A cohort and 15 
% (0, 39 %, (p = 0.35) in the high BCL11A 
cohort. There is a considerable relationship 
between the transcript levels of BCL11A during 
diagnosis with several clinical and laboratory 
variables. While, no significant correlation was 
detected between complete remission rate and 
survival. These data indicate that BCL11A 
expression possibly plays role in AML [1]. 
 
Currently, the clinical outcomes of 51 AML 
patients who were subjected to transplantation 
were evaluated using a standardized reduced-
intensity conditioning treatment that incorporates 
post-transplantation azacitidine (AZA).They 
discovered that 14 patients did not initiate AZA 
either because of extraction of permission or 
transplantation impediments. It was noted that 37 
patients initiated AZA for durations ranging from 
40-194 days (median of 54 days) after 
transplantation. 37 patients completed 3 or more 
cycles of AZA, while 16 patients relapsed 8 
months (median time) after transplantation. No 
patient was observed to develop widespread 
chronic graft-versus-host disease. It was thus 
inferred that the AZA is well accepted after 
transplantation and appears to have the potential 
to lower the relapse risk in patients who display a 
CD8+ T cell response to tumor antigens [17]. 
 
A study was carried out to assess the 
epidemiological profile and the chances of 
survival of AML patients in a Hospital Infantil 
Joana de Gusmão. 51 patients diagnosed with 
AML between 2004 and 2012 were included in 
this study. Of the 51 patients studied, 84 % were 
white; 45 % were females and 55 % were males. 
In addition, 8 % of the patients were below 1 
year, 47 % were aged between 1 and 10 years, 
and 45 % were older than 10 years. The major 
symptoms reported for the patients were fever 
(41.1 %), asthenia (35.2 %), and hemorrhagic 
manifestations (27.4 %). The central nervous 
system was the most affected extra-medullary 
site (14 %). Diagnosis showed WBC count of 
below 10,000/mm3 in 47 % of patients. The 
minimal residual disease (MRD) was determined 
to be < 0.1 % on the 15th day of treatment in 16 
% of the sample. Medullary relapse arose in 14 
% of cases. Comparative analysis between the 
bone marrow MRD and the vital status showed 
that 71.42 % and 54.05 % of the patients with 
type M3 AML and non-M3 AML, respectively, 
were alive. Mortality rate of 43 % was then 
reported, attributable to septic shock (63.6 %) 
[18]. 
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In a different study, 2-DE-based proteomics was 
used to investigate cisplatin-induced effects in 
vitro of human liver cells (L02). The major 
objective of the study was to identify proteomic 
responses, which were subsequently used as 
endpoints to determine the dose responsive 
effects of cisplatin in human liver L02 cells in 
three different concentrations (1 nM, 1 M and 1 
mM). The results of this study suggest that 
instabilities in protein synthesis and oxidative 
stress by differential mechanisms were induced 
due to the different cisplatin treatments. Given 
that the experimental concentrations of cisplatin 
exhibit a hormesis effect in cell proliferation of 
L02 cells, proteomic markers are expected to 
denote this hormesis effects. A hormesis effects 
with a U-shape regulation were discernible from 
up-regulation of confilin-1 among the three 
concentrations used in cisplatin treatments. The 
results are consistent with toxico-proteomic 
studies, which pointed out that the toxico-
proteomic responses based on dose-dependent 
protein responses are incongruent with the 
theoretically linear or hormetic concentration–
effect relationship. These findings suggest that 
the proteomic responses induced by cisplatin 
treatments do not have the ability to reflect a 
macroscopic hormesis phenomenon on cell 
proliferation [19]. 
 
Last study was carried out using different elution 
conditions to improve the recovery of all classes 
of proteins and maintain their compatibility with 
immunoblotting techniques. The use of double 
elution and formic acid combined with urea was 
found to be the most efficient and commonly 
applicable elution method for chemical 
proteomics [20]. Also, the prognostic role of AKT 
mediated GSK3 phosphorylation in AML was 
examined to explore the GSK3α/β 
phosphorylation using reverse phase protein 
analysis (RPPA) in a group of 511 AML patients 
[21]. They found a positive correlation between 
levels of phosphorylated GSK3 versus patient 
survival and expression of other proteins in AML 
cell survival. The study also showed that high 
levels of p-GSK3α/β are correlatable with 
adverse general survival and a lower occurrence 
of complete relapse duration in patients with 
intermediate cytogenetics. In contrast, no 
correlation was observed in those with 
unfavorable cytogenetics. Intermediate 
cytogenetic patients with FLT3 mutation showed 
a correlation at low rates of p-GSK3α/β. 
Phosphorylated GSK3α/β expression was 
evaluated against that of 229 related cell cycle 
arrest and/or apoptosis proteins [21].  
 
RPPA showed that p-GSK3α/β is positively 
correlatable with phosphorylation of AKT, BAD, 
and P70S6K, but negatively correlated with β-
catenin and FOXO3A. In addition, the positive 
correlation between PKCδ and p-GSK3α/β 
expression suggest a crosstalk between the AKT 
and PKC signaling pathways in AML cells. It was 
inferred from their findings that AKT-mediated 
phosphorylation of GSK3α/β may promote the 
survival of AML cells, and thus damaging to the 
overall survival of AML patients. Therefore, p-
GSK3α/β basically serves as a significant 
adverse prognostic factor for a subset of AML 
patients [21]. 
 
In another study, the safety, maximum tolerated 
dose (MTD), and dose-limiting toxicity (DLT) of 
ruxolitinib at doses of 50, 100, and 200 mg b.i.d. 
in patients with relapsed/refractory AML were 
evaluated. Twenty seven patients older than 14 y 
(26 relapsed or refractory AML and 1 patient was 
affected by acute lymphoid leukaemia) were 
signed up in this study. It was deduced that the 
patient with multiple relapses and incomplete 
recovery of peripheral blood counts was 
subjected to 7 lines therapy [6]. 
 
Furthermore, the levels of expression of TRIM62 
protein in 511 AML patients were explored using 
reverse-phase protein array technology. It was 
observed that low levels of TRIM62 are related to 
markedly poorer outcomes but enhances the 
prognostic impact of Nucleophosphamin-
1(NPM1) and FLT3 mutations. Therefore, low 
level of TRIM62 is an independent adverse 
prognostic factor in AML consistent with a tumor 
inhibiting role [22]. Similarly, kinase activity 
profiling was used to recognize collaborators of 
Spleen Tyrosine Kinase (SYK) in AML. It was 
observed that FMS-like tyrosine kinase 3 (FLT3) 
is trans-activated by SYK via direct binding. 
FLT3-ITD positive AML presented highly 
activated SYK which binds to FLT3-ITD to 
activate MYC transcriptional programs. SYK was 
highly suppressed with FLT3-ITD AML cells 
rather than FLT3 wild-type complements. It was 
thus inferred that in vivo model FLT3-ITD, SYK is 
critical for myeloproliferative disease (MPD) 
development. Over expression of SYK facilitates 
transformation to AML and resistance to FLT3-
ITD-targeted therapy [23]. 
 
Studies were also performed to chemically adapt 
oligonucleotide aptamers with different functional 
molecules and it can bind specifically with 
biomarkers on cancer cells to be used in treating 
AML [24,25]. To target AML cells, a single-strand 
DNA aptamer specific for CD117 biomarker was 
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developed. Sequence alignment exhibited that 
the aptamer contained a G-rich core region with 
a well-conserved functional G-quadruplex 
structure [26]. Functional assays demonstrated 
that this synthetic aptamer was able to 
specifically precipitate CD117 proteins from cell 
lysates, selectively bound cultured and patient 
primary AML cells with high affinity (Kd< 5 nM), 
and was specifically internalized into CD117-
expressing cells [26]. Exposure of patient marrow 
specimens to aptamer-methotrexate (Apt-MTX) 
resulted in selective growth inhibition of primary 
AML cells and had no toxicity to off-target 
background normal marrow cells within the same 
specimens. The result of this study showed that 
the Apt-MTX presented a potential clinical value 
for AML therapy with minimal to no side effects in 
patients. The Apt-MTX opens an avenue to 
chemical synthesis of new targeted 
biotherapeutics [26]. 
 
An earlier study investigated the proteome 
analysis of four AML cell lines (NB4, THP1, K562 
and HL60), one chronic myeloid leukaemia 
(CML) cell line and of granulocytes isolated from 
normal human peripheral blood [27]. 823 proteins 
were identified and relatively quantified using cell 
surface biotinylation, followed by capture on 
streptavidin resin, tryptic digestion and Deep 
QuanTR-assisted mass spectrometric analysis. 
CD166 or Activated Leukocyte Cell Adhesion 
Molecule (CD166/ ALCAM) protein was studied 
at length, because it has been proven to be 
strongly up-regulated in all AML cell lines, 
compared to CML and granulocyte controls [28]. 
More than 100 identified proteins (such as CD33, 
CD166, integrin alpha-4 and embigin) were found 
to be relatively more up-regulated in the AML cell 
lines compared to granulocytes.  In addition, the 
duocarmycin derivatives were found to be more 
effective compared to the microtubule-targeting 
cemadotins and maytansinoids. The outcomes of 
the study were consistent with fluorescence-
activated cell sorting (FACS) validation 
experiments which could be developed into the 
basis for antibody-based drug development 
programs which target human leukaemia [27]. 
 
In addition, the expressions of miRNA profiles of 
cell lines were studied along with differential 
expression analysis and target prediction of 
numerous miRNA signatures in both AML and 
CML cell lines [29]. The miRNome of two human 
AML cell lines (HL-60 and THP-1) and one 
human CML cell line (K-562) were analyzed 
using vastly parallel signature sequencing. Some 
miRNAs may possibly act through tumor 
suppressors or oncomiRs contained in AML and 
CML cell lines by targeting key genes in AML 
and CML pathways. Thus, characteristics of K-
562, HL-60 and THP-1 cell lines such as actin 
filament-based processes, reaction to stimulus 
and phagocytic activity can be evaluated via 
expression patterns of cell type-specific miRNAs. 
It was also recommended that miRNA scan 
regulate myeloid differentiation, since they 
generally inhibit differentiation regulators. The 
study provided a basis to further study the use of 
miRNAs in human leukaemia subtyping, 
leukemogenesis and myeloid development. In 
addition, the unique miRNA signatures were 
suggested as potential candidates for the clinical 
diagnosis, prognosis and treatment of myeloid 
leukaemia [29]. 
 
Likewise, the potential mechanism essential to 
the regulation and expression of B55α, in 
addition to the likely role of the B subunit as a 
tumor suppressor in AML were comprehensively 
studied [30]. A strong correlation was observed 
between B55α and several proteins (including 
MYC, PKCα, and SRC) after reverse phase 
protein analysis (RPPA) of 230 proteins in 511 
AML patients. B55α suppression in OCI-AML3 
cells by shRNA indicated that the B subunit is a 
PKCα phosphatase. Rather than target SRC, the 
kinase (B55α) suppresses protein expression of 
the B subunit. Lastly, the correlation between 
B55α and MYC levels reflected a complex 
stoichiometric competition between B subunits. 
Loss of B55α in OCI-AML3 cells did not change 
global PP2A activity and only the isoform 
containing B56α is induced. In cells containing 
B55α shRNA, MYC was suppressed with 
simultaneous induction of the competing B 
subunit B56α (PPP2R5A). A current study also 
determined that FTY-720, a drug whose 
mechanism entails the activation of PP2A, 
resulting in the induction of B55α in AML cells, 
and a reduction of the B subunit that renders 
these cells resistant to FTY-720 increase the 
expression of miR-191-5p and a suppression of 
miR-142-3pcan be attributable to reduction of the 
B subunit. Interestingly, miRs were greatly 
regulated by B55α and a poor survival in AML 
was indicated by high levels of miR-191. The 
miR-142-3p was mutated in approximately 2 % of 
AML patients. Conclusively, the suppression of 
B55α activates signaling pathways that could 
guarantee the survival of leukaemia cells [30]. 
The validity of applying the proteomic profiling 
would require comprehensive verification via 
clinical trials on mice or by using advanced and 
sensitive molecular assays such as western plot 
(WP) or RT-PCR. To overcome some of the 
aforementioned problems, particularly in the 
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biomarker discovery phase, genetically stable 
models of mice with the disease would simplify 
the initial use of protein biomarker for candidate 
selection [31]. 
 
A comparative study was done to analyze the 
efficacies of three high-abundance protein 
removal methods using 2-DG. The studied 
methods include the ProteoPrep® Blue Albumin 
and IgG Depletion Kit (Sigma–Aldrich, USA), the 
ProteoPrep® Immunoaffinity Albumin and IgG 
Depletion Kit (Sigma–Aldrich, USA), and the 
Albumin and IgG Depletion SpinTrap Kit 
(Amersham Biosciences, Sweden). Their study 
showed that high-abundance proteins were 
removed with greatest efficiency using the 
ProteoPrep® Immunoaffinity Albumin and IgG 
Depletion Kit and the Albumin and IgG Depletion 
SpinTrap Kit[32]. An earlier study highlighted that 
majority of AML patients who tolerate the 
treatment were able to attain complete remission 
after chemotherapy, although these patients 
relapse a few years after remission [33].  
 
The majority of proteomic studies on bone 
marrow and peripheral blood cells in AML were 
only performed at time of diagnosis. Hence, not 
much is known about the proteomic profile of the 
bone marrow and peripheral blood cells at 
remission or relapse [2], although, one study 
attempted to comparatively analyze AML at 
diagnosis, following remission, and at 
recurrence. No significant difference was 
observed in the mononuclear cell proteomic 
profiles between AML patients at diagnosis and 
recurrence. Therefore, it was suggested that the 
proteome expressions of cells before treatment 
and at relapse are similar, in any case at the 
level of high concentration of proteins [2]. In 
2012, one study also carried out by Luczak et al 
to identify proteins in the bone marrow and 
peripheral blood samples collected from healthy 
subjects and patients with AML-M1/M2. 25 
proteins demonstrated differential expression. 
Based on the findings, the AML samples were 
readily grouped into M1 and M2 AML.  However, 
only the M2 AML group showed expression of 6-
phosphogluconate dehydrogenase, L-plastin, 
and Annexin III [3]. 
 
Quantitative phosphoproteomics was 
investigated in order to recognize gefitinib- and 
erlotinib stimulated transformations on the level 
of site-specific serine, threonine and tyrosine 
phosphorylation in AML cells [34]. The affinities 
of direct AML cell targets for both kinase 
inhibitors were evaluated using quantitative 
chemical proteomics. SILAC-based quantitative 
mass spectrometry was applied to examine 
10,975 distinct phosphorylation sites to 
characterize the phosphoproteome of KG1 AML 
cells and its regulation upon erlotinib and gefitinib 
treatment. It was reported that less than 50 site-
specific phosphorylations were considerably 
altered, exhibiting specific interference with AML 
cell signaling. The data proposed that cellular 
distortion of SFKs and/ or Btk transform into 
rather specific signal transduction inhibition, 
which induces the antileukaemic activity of 
erlotinib and gefitinib in AML, respectively [34]. 
 
2-DGsystems and MALDI-TOF/MS were used to 
study the protein expression in AML1/ETO 
positive cells in order to illustrate the mechanism 
of azacitidine (AZA) and decitabine (DAC), in 
addition to determining their biological activity in 
Kasumi-1 cells [35]. Cyclophilin A, catalase, 
nucleophosmin and PCNA were decreased 
exclusively by azacitidine only, while TCP1 and 
hnRNP A2/B1 were decreased by both drugs 
(AZA and DAC). Alpha-Enolase and 
Peroxiredoxin-1 showed decreased after 
treatment with decitabine. Of interest, is the fact 
that Cyclophilin A was also proposed as a 
marker of cell necrosis, which was stimulated by 
decitabine [35]. AZA and DAC displayed diverse 
mechanisms consistent with their activities on 
cell viability, protein synthesis, cell cycle, miRNA 
and gene expression [36-38]. AZA and DAC 
exhibit specific and discriminatory modulations of 
the target proteins which are in agreement with 
the proposed theory which hypothesizes that 
these two agents exhibit different mechanisms. 
Despite the dissimilarity between AZA and DAC, 
they can be used in clinics in alternating or 




Proteomics is an obvious approach for profiling 
acute myeloid leukaemia because proteins 
change with cellular responses to internal 
environment, external stimuli, and disease 
development. The quest to transform basic 
discoveries into patient care regimes has 
resulted in several proteomic studies being 
carried out to profile potential biomarkers. 
However, it is disappointing that despite the 
technological advancement in the field, very few 
studies have manifested into clinical trials. It is 
thus vital that polypeptides identified as potential 
biomarkers are validated in suitably processed 
and well-characterized clinical samples using 
recognized techniques such as immunochemistry 
or PCR-based methods as pointed out in the 
review. 
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Table 1: Summary of studies investigating proteomic profiles of acute myeloid leukaemia 
 
Target Used method Sample  Reference  
 
Study the associations between BCL11A 




292 AML patients  
 
[1] 
Assessment of AML patients subjected to 
transplantation 
 SRIC incorporating 
post-transplantation 
AZA 
51 AML patients [17] 
Investigating the epidemiological profile and 





51 AML patients [18] 
Investigate cisplatin-induced effects in vitro of 
human liver cells (L02).  
2-DE In vitro model of human liver 
cells (L02) 
[19] 
Improve the recovery of all classes of 




coupled with mass 
spectrometry (LCMS)  
K-562 and HEL cells  [20] 
Study the prognostic role of AKT mediated 




511 AML patients [21] 
Evaluation of the safety, MTD and DLT of 
ruxolitinib patients with relapsed/refractory 
AML 
A single-center phase 
I/II clinical study testing 
3 dose levels (50 mg 
(n=4), 100 mg  (n=5), 
and 200 mg (n=18) 
27 AML patients [6] 




511 AML patients [22] 
Identification of collaborators of Spleen 
Tyrosine Kinase (SYK) in AML 
kinase activity profiling  A bead-based screening 
technology to profile the 
phosphorylation state of 80 
receptor and non-receptor 
tyrosine kinases in AML cell 
lines 
[23] 
Develop new therapeutics targeting AML A single-strand DNA 
aptamer specific for 
CD117 biomarker 
Aptamer-drug conjugates 
were fabricated by chemical 
synthesis of Apt MTX, a 
central drug used in AML 
chemotherapy regimens. 
[26] 
Investigate the proteome analysis of four 
AML cell lines (NB4, THP1, PLB985, and HL-
60) and one CML (K-562) 
Cell surface 
biotinylation and mass 
spectrometric analysis 
Five human myeloid 
leukemia cell lines and 
normal human granulocytes, 
which was used  
[27] 
Study the expression of miRNA profiles of 
two human AML cell lines (HL-60 and THP-
1), and one human CML cell line (K-562) 
followed by differential expression analysis 
and target prediction 
Massively parallel 
sequencing for an in-
depth analysis of the 
miRNomes 
Three myeloid leukemia cell 
lines 
[29] 
Investigation of the potential mechanism 
underlying the regulation and expression of 
B55α, in addition to the possible role for the B 
subunit as a tumor suppressor in AML 
RPPA of 230 proteins  511 AML patients [30] 
Comparison between the efficiency of three 
high-abundance protein depletion methods 
SDS–PAGE  and 2-DG ProteoPrep Blue Albumin 
and IgG Depletion Kit, 
ProteoPrepImmunoaffinity 
Albumin and IgG Depletion 
Kit and Albumin and IgG 
Depletion SpinTrap Kit 
[32] 
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Table 1: Summary of studies investigating proteomic profiles of acute myeloid leukaemia (Continued) 
 
Target Used method Sample  Reference  
 




reported clinical trials  
  
[33] 
Compare between proteome expression of 
cells prior to treatment and at relapse 
2-DG, Gel image 
analysis and mass 
spectrometry 
38 AML (M1 or M2) patients  [2] 
Investigation of the quantitative 
phosphoproteomics to identify gefitinib- and 
erlotinib induced changes on the level of site-
specific serine, threonine and tyrosine 





phosphorylation sites for 
characterization of the KG1 
AML cells phosphoproteome 
[34] 
Examine the protein expression in 
AML1/ETO positive cells to illustrate the 
mechanism of action of azacitidine and 
decitabine, as well as to determine their 
biological activity  
2-DG system, followed 
by MALDI-TOF/MS 
Kasumi-1 cells [35] 
SRIC; Standardized Reduced-Intensity Conditioning, AZA; Azacitidine , Rt; Reverse Transcriptase, RT-PCR;Real 
Time-Polymerase Chain Reaction, 2-De; Two-Dimensional Electrophoresis, RPPA; Reverse Phase Protein 
Analysis, MTD; Maximum Tolerated Dose, AML; Acute Myeloid Leukaemia, Apt; Aptamer, MTX; Methotrexate, 
CML; Chronic Myeloid Leukaemia, HL-60; acute promyelocytic leukemia, THP-1; Acute Monocytic Leukemia,  
PLB985; acute myeloid leukemia (derivative of HL-60) K-562; Chronic Myleoid Leukaemia, Kasumi-1; Human 
Acute Myeloid Leukemia, NPM; Nucleophosphamin, MDS; Myelodysplastic Syndrome, KG1; acute myelogenous 
leukemia, LCMS; Liquid Chromatography Mass Spectrometry 
 
This is important given that understanding the 
molecular mechanisms in treatment responses 
and disease recurrence is limited in AML. The 
majority of obtainable biomarkers are single 
biomolecules with low sensitivity and specificity. 
Therefore, the use of a combination of 
measurable protein panels for a more accurate 
diagnosis and prediction of disease prognosis in 
AML is highly recommended based on the 
review. Proteome analysis was also shown to 
form a link between gene expressions and 
cellular function, which can be used afterwards to 
evaluate disease growth, prognosis and reaction 
to treatment. Moreover, by mapping the location 
of proteins in cells (proteome analysis); it is 
possible to examine molecular and biological 
mechanisms. Based on the review and the 
inherent benefits of proteome analysis, this paper 
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